PharmaEssentia

6446.TW

17.32 USD

-0.21

-1.20%

Overview

Last close

17.32 usd

Market cap

5.91B usd

52 week high

22.96 usd

52 week low

8.77 usd

Target price

26.18 usd

Valuation

P/E

101.982

Forward P/E

N/A

Price/Sales

26.4068

Price/Book Value

6.9985

Enterprise Value

4.99B usd

EV/Revenue

19.5572

EV/EBITDA

69.9518

Key financials

Revenue TTM

212.06M usd

Gross Profit TTM

N/A usd

EBITDA TTM

-6.61M usd

Earnings per Share

0.17 usd

Dividend

N/A usd

Total assets

28.20B usd

Net debt

-18.98B usd

About

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.